Nephros
NEPH
14 hedge funds and large institutions have $6.35M invested in Nephros in 2023 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 3 closing their positions.
0.09% more ownership
Funds ownership: 40.8% → 40.89% (+0.09%)
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
4% less capital invested
Capital invested by funds: $6.63M → $6.35M (-$286K)
13% less funds holding
Funds holding: 16 → 14 (-2)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WC
Wexford Capital
West Palm Beach,
Florida
|
+$44.6K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$9.54K |
| 3 |
JP Morgan Chase
New York
|
+$12 |
| 4 |
Wells Fargo
San Francisco,
California
|
+$3 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$21K |
| 2 |
BA
Bard Associates
Chicago,
Illinois
|
-$10.3K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$9.38K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$488 |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
-$8 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
WC
1
Wexford Capital
West Palm Beach,
Florida
| $5.46M | +$44.6K | +29,973 | +0.8% |
|
|
BA
2
Bard Associates
Chicago,
Illinois
| $275K | -$10.3K | -6,900 | -4% |
|
|
3
Vanguard Group
Malvern,
Pennsylvania
| $253K | +$9.54K | +6,414 | +4% |
|
|
4
Geode Capital Management
Boston,
Massachusetts
| $106K | -$9.38K | -6,307 | -8% |
|
5
HighTower Advisors
Chicago,
Illinois
| $83K | – | – | – |
|
|
EP
6
Elkhorn Partners
Omaha,
Nebraska
| $67K | – | – | – |
|
7
William Blair & Company
Chicago,
Illinois
| $53.6K | – | – | – |
|
8
State Street
Boston,
Massachusetts
| $23.5K | – | – | – |
|
9
Morgan Stanley
New York
| $22.6K | – | – | – |
|
10
BlackRock
New York
| $6.11K | – | – | – |
|
|
TRCT
11
Tower Research Capital (TRC)
New York
| $334 | -$488 | -328 | -59% |
|
|
12
Wells Fargo
San Francisco,
California
| $101 | +$3 | +2 | +3% |
|
13
UBS Group
Zurich,
Switzerland
| $16 | – | – | – |
|
|
14
JP Morgan Chase
New York
| $12 | +$12 | +8 | New |
|
|
15
Renaissance Technologies
New York
| – | -$21K | -13,705 | Closed |
|
|
16
Osaic Holdings
Scottsdale,
Arizona
| – | -$8 | -5 | Closed |
|
NEPH Hedge Fund Activity: Q3 2023 in Review
14 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Nephros (NEPH) for Q3 2023, worth a combined $6.35M — down 4.3% from $6.63M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of NEPH and 1 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 3 added.
The largest buyer was Wexford Capital, adding an estimated $44.6K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $21K sold.
- 14 institutional investors held Nephros (NEPH) as of Q3 2023, down from 16 in Q2 2023.
- Funds reported $6.35M of Nephros stock for Q3 2023, down 4.3% quarter-over-quarter.
- 1 fund opened new Nephros positions in Q3 2023 and 3 closed out, a net change of -2 holders.
- The largest Nephros buyer in Q3 2023 was Wexford Capital, an estimated $44.6K added.
- The largest Nephros seller in Q3 2023 was Renaissance Technologies, an estimated $21K sold.
Based on aggregated 13F filings for Q3 2023.